Jazz Pharmaceuticals (JAZZ) announced new real-world evidence and Phase 4 data reinforcing the value of Xywav oral solution treatment outcomes in adults with narcolepsy or idiopathic hypersomnia were presented at World Sleep 2025, held in Singapore from September 5-10, 2025, as well as the 38th annual Psych Congress, held in San Diego from September 17-21, 2025. Notable Phase 4 data included new results from the DUET trial, showing treatment effects of low-sodium Xywav on daytime and nighttime symptoms of narcolepsy or IH.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- Avadel says court requires 3.85% of Lumryz sales go to Jazz
- Jazz Pharmaceuticals’ ZW25 Study Update: A Potential Game-Changer in Cancer Treatment
- Jazz Pharmaceuticals’ Modeyso recommended for glioma by NCCN Guidelines
- Kohl’s, Bill.com, Novavax, Jazz, Nvidia: Trending by Analysts
- Jazz Pharmaceuticals’ Pregnancy Study on Epidiolex: Key Insights for Investors